Endo International plc (ENDP)
(Delayed Data from NSDQ)
$8.20 USD
+0.48 (6.22%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.19 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.20 USD
+0.48 (6.22%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.19 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Johnson & Johnson's (JNJ) Legal Problems Continue to Worry Investors
by Christopher Vargas
Johnson & Johnson (JNJ) is set to report their third quarter results as pending lawsuits loom over the company.
J&J Settles Ahead of Multi-District Opioid Trial, Stock Up
by Zacks Equity Research
J&J (JNJ) reaches settlement agreement with Cuyahoga and Summit counties in Ohio concerning the lawsuits pending in MDL.
Mallinckrodt Up on Settlement Agreement With Ohio Counties
by Zacks Equity Research
Mallinckrodt (MNK) gains on the execution of a settlement agreement with Cuyahoga and Summit Counties in Ohio concerning the lawsuits pending in MDL.
Mallinckrodt's StrataGraft Tissue Phase III Data Positive
by Zacks Equity Research
Mallinckrodt's (MNK) experimental StrataGraft regenerative tissue meets goals in a late-stage study for the treatment of burns.
Mallinckrodt to Divest Contract Manufacturing Unit, Stock Up
by Zacks Equity Research
Mallinckrodt's (MNK) shares gain as it agrees to sell its contract manufacturing unit to raise cash to settle liabilities from various opioid litigations.
Endo Files BLA for CCH With the FDA for Cellulite Candidate (Revised)
by Zacks Equity Research
Endo International (ENDP) files BLA for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.
Mallinckrodt (MNK) to Resolve Opioid Cases with Ohio Counties
by Zacks Equity Research
Mallinckrodt (MNK) reaches a settlement in principle with a couple of Ohio counties for opioid litigation.
Endo International Files BLA for Label Expansion of Xiaflex
by Zacks Equity Research
Endo International (ENDP) files BLA for the additional indication of Xiaflex [collagenase clostridium histolyticum (CCH)] for the treatment of cellulite in the buttocks.
Mallinckrodt Mulls Bankruptcy Ahead of Major Opioid Litigation
by Zacks Equity Research
Mallinckrodt (MNK) plunges as the risk of filing for bankruptcy rises ahead of the multi-district opioid litigation scheduled next month.
Endo Gains FDA Nod for Orfadin Generic to Treat Rare Disease
by Zacks Equity Research
Endo (ENDP) receives an FDA approval for the generic equivalent of Swedish Orphan Biovitrum's Orfadin.
Endo (ENDP) Up 5.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allergan Settles Ahead of Multi-District Opioid Litigation
by Zacks Equity Research
Allergan (AGN) settles with two counties of Ohio for $5 million related to the upcoming multidistrict litigation for opioid-based drug abuse.
Will Opioid Litigation Take its Toll on Pharma Companies?
by Indrajit Bandyopadhyay
Thousands of pending opioid-abuse lawsuits against several pharma companies come into limelight after the Oklahoma ruling against J&J. Let's see what's in store for these companies.
J&J Up Despite $572M Fine in Oklahoma Opioid Abuse Case
by Zacks Equity Research
A court ordered J&J (JNJ) to pay $527 million in the Oklahoma litigation related to abuse of its opioid-based drugs. The company is facing similar litigation in multiple states.
Case-Shiller Index Nudges Up
by Zacks Equity Research
Case-Shiller Index Nudges Up
J&J to Pay $572M in Opioid Case; Plus Case-Shiller Home Price Read
by Mark Vickery
Johnson & Johnson (JNJ) now owes $572 million, as per the judge in this case, which pits J&J responsible for rampant opioid use.
J&J's (JNJ) Opioid Lawsuit Verdict in Oklahoma Due Next Week
by Zacks Equity Research
J&J (JNJ) is facing several litigation in multiple states related to abuse of its opioid-based drugs. A ruling is expected on Aug 26 in a trial filed by the state of Oklahoma.
Mallinckrodt (MNK) Stock Down 70.8% YTD on Numerous Lawsuits
by Zacks Equity Research
Mallinckrodt (MNK) crashes 70.8% in the year so far due to various lawsuits and litigations.
Endo Up on Settlement of a Few Cases Related to Opioid Drugs
by Zacks Equity Research
Endo (ENDP) finally has some good news for investors with the settlement of a few cases in Ohio related to opioid medications.
Are Options Traders Betting on a Big Move in Endo (ENDP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Endo (ENDP) stock based on the movements in the options market lately.
Is Endo International (ENDP) A Great Pick for Value Investors?
by Zacks Equity Research
Is Endo International Holdings (ENDP) a great pick from the value investor's perspective right now? Read on to know more.
BioDelivery (BDSI) Earnings & Sales Beat Estimates in Q2
by Zacks Equity Research
BioDelivery (BDSI) reports earnings against expectations of loss in Q2 and raises guidance for 2019.
Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y
by Zacks Equity Research
Endo (ENDP) beats on both sales and earnings in the second quarter of 2019. However, both metrics decline year over year due to weak generic business.
Endo International (ENDP) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Endo (ENDP) delivered earnings and revenue surprises of 10.64% and 0.37%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Endo International (ENDP) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Endo (ENDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.